Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden.

Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F.

doi:10.1007/s00228-012-1377-4

PURPOSE: Our aim was to evaluate whether dronedarone authorization impacts antiarrhythmic drug prescribing in Sweden and Emilia Romagna (Italy). METHODS: Prescriptions of classes I and III antiarrhythmics, expressed as defined daily doses per thousand inhabitants per day (DDD/TID) were monthly using information collected from pharmacy-reimbursed databases. Interrupted time series analysis was applied to compare prescription data over the 2009-2011 period. RESULTS: In Emilia Romagna, the overall consumption of antiarrhythmics was six times as high as in Sweden (7.6 vs. 1.2 DDD/TID). In the first year on the market, dronedarone represented 1.0 % in Italy and 10.7 % in Sweden of the overall antiarrhythmic prescriptions. In Sweden, dronedarone authorization generated an increase in the prescription trend of antiarrhythmics (trend change +0.02; p < 0.001) without variation in amiodarone use In Emilia Romagna, dronedarone marketing did not influence the prescription pattern of either overall antiarrhythmics or amiodarone. CONCLUSIONS: Emilia Romagna and Sweden substantially differ in terms of overall antiarrhythmic use. Although clinical guidelines place dronedarone among first-choice treatments for atrial fibrillation, amiodarone prescribing was not affected in either country by the entry of dronedarone, probably due to a cautious approach by clinicians in line with regulatory recommendations and safety warnings.

Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden / Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - 69:3(2013), pp. 715-720.

Data di pubblicazione:	2013
Titolo:	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden.
Autore/i:	Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F.
Autore/i UNIMORE:	Piccinni C Raschi E Poluzzi E Puccini A Cars T Wettermark B Diemberger I BORIANI, Giuseppe De Ponti F. mostra contributor esterni nascondi contributor esterni
Digital Object Identifier (DOI):	http://dx.doi.org/10.1007/s00228-012-1377-4
Rivista:	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume:	69
Fascicolo:	3
Pagina iniziale:	715
Pagina finale:	720
Codice identificativo ISI:	WOS:000317335200049
Codice identificativo Scopus:	2-s2.0-84877154061
Codice identificativo Pubmed:	22941408
Citazione:	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden / Piccinni, C; Raschi, E; Poluzzi, E; Puccini, A; Cars, T; Wettermark, B; Diemberger, I; Boriani, Giuseppe; De Ponti, F.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - 69:3(2013), pp. 715-720.
Tipologia	Articolo su rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11380/1080351

Citazioni

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris